Biochemical Diagnostic Significance of Cannabis Indica Misuse in Society- A Socio-Behavioral Validation Study
DOI:
https://doi.org/10.53350/pjmhs020231711584Keywords:
Cannabis indica, misuse, cannabis use disorder, behavioral screening, Kashmir, public health.Abstract
Introduction: Cannabis indica, usually known as weed, has transitioned from a traditional herb to a widely misused psychoactive substance. While its medicinal value is acknowledged, its misuse especially among youth has become a silent epidemic. The normalization of recreational use, increased potency, and early exposure have contributed to a rise in cannabis use disorder (CUD), cognitive decline, and social dysfunction.
Objective: To determine the diagnostic significance of Cannabis indica misuse in society using behavioral screening tools as the gold standard.
Study Design: Cross-sectional validation study.
Material and Methods: A cross-sectional validation study was conducted on 140 individuals aged 15–45 years in urban centers of Kashmir from 01-01-2025 to 01-07-2025. Participants were screened for cannabis misuse using self-reported frequency, DSM-5 criteria, and the Cannabis Use Disorder Identification Test-Revised (CUDIT-R). Behavioral assessments were used as the gold standard.
Results: Among 140 participants, 94 (67.1%) were under 30 years of age. 46 (32.9%) were over 30. 48 individuals (34.3%) met criteria for cannabis misuse, while 92 (65.7%) did not. Of these, 36 were true positives, 12 false positives, 80 true negatives, and 12 false negatives. The sensitivity of self-reported cannabis misuse was 75.0%, specificity 86.9%, positive predictive value 75.0%, and negative predictive value 86.9%.
Conclusion: Cannabis misuse is underreported and often masked by cultural normalization. While self-reporting shows moderate sensitivity, behavioral screening tools offer higher diagnostic reliability. Early detection and intervention are essential to mitigate long-term harm.
References
United Nations Office on Drugs and Crime. World Drug Report 2024.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), 2022.
National Institute on Drug Abuse. Cannabis Research Report, 2025.
Bashir, A., & Wani, M. (2024). Substance Use Patterns in Conflict Zones: A Case Study of Kashmir. Journal of South Asian Public Health, 12(1), 45–58.
Hall, W., & Degenhardt, L. (2023). The adverse health effects of chronic cannabis use. The Lancet Psychiatry, 10(3), 210–222.
Goyal, R. et al. (2025). Cannabis Use Disorder in South Asia: Trends and Interventions. Asian Journal of Psychiatry, 78, 102–110.
Huestis MA et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322 (2001). [DOI] [PubMed] [Google Scholar]
Kubilius RA, Kaplick PM & Wotjak CT Highway to hell or magic smoke? The dose-dependence of Δ9-THC in place conditioning paradigms. Learn. Mem. 25, 446–454 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
Le Foll B & Goldberg SR Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312, 875–883 (2005). [DOI] [PubMed] [Google Scholar]
Panlilio LV, Justinova Z, Trigo JM & Le Foll B Screening medications for the treatment of cannabis use disorder. Int. Rev. Neurobiol. 126, 87–120 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
Schindler CW et al. Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. Neuropsychopharmacol 41, 2283–2293 (2016). This work compares the attenuation of nicotine and THC reinforcement and reinstatement using the CB1 receptor inverse agonist rimonabant and the CB1 receptor neutral antagonist AM4113, highlighting the potential utility of neutral antagonists in treating tobacco and cannabis dependence.
Justinova Z, Tanda G, Munzar P & Goldberg SR The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173, 186–194 (2004). This work demonstrates for the first time the modulation of the reinforcing effects of THC self-administration of the opioid antagonist naltrexone.
Bossert JM, Marchant NJ, Calu DJ & Shaham Y The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 229, 453–476 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
Freels TG et al. Vaporized cannabis extracts have reinforcing properties and support conditioned drug-seeking behavior in rats. J. Neurosci. 40, 1897–1908 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
Tanda G, Pontieri FE & Di Chiara G Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048–2050 (1997). [DOI] [PubMed] [Google Scholar]
Ibrahim C et al. The insula: a brain stimulation target for the treatment of addiction. Front. Pharmacol. 10, 720 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
Kodas E, Cohen C, Louis C & Griebel G Corticolimbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology 194, 161–171 (2007). [DOI] [PubMed] [Google Scholar]
Haney M et al. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38, 1557–1565 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
D’Souza DC et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 60–67 (2016). [DOI] [PubMed] [Google Scholar]
Haney M et al. Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology 29, 158–170 (2004). [DOI] [PubMed] [Google Scholar]
Trigo JM et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol. Depend. 161, 298–306 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
D’Souza DC et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6, 35–45 (2019). [DOI] [PubMed] [Google Scholar]
Sloan ME, Grant CW, Gowin JL, Ramchandani VA & Le Foll B Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. Acta Pharmacol. Sin. 40, 342–350 (2019). This review examines differences in cannabinoid signalling in individuals with psychiatric disorders and controls, demonstrating reduced CB1 binding in cannabis users.
Hirvonen J et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 17, 642–649 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
Di Marzo V et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9-tetrahydrocannabinol-tolerant rats. J. Neurochem. 74, 1627–1635 (2002). [DOI] [PubMed] [Google Scholar]
Morgan CJA et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J. Psychiatry 202, 381–382 (2013). [DOI] [PubMed] [Google Scholar]
Boileau I et al. Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C]CURB. Biol. Psychiatry 80, 691–701 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
Koob GF & Volkow ND Neurocircuitry of addiction. Neuropsychopharmacology 35, 217–238 (2010). This review delineates the neural circuits underlying drug use, abuse and addiction, drawing on animal and human imaging work.
Sevy S et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology 197, 549–556 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
Stokes PR et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J. Psychopharmacol. 26, 144–149 (2012). [DOI] [PubMed] [Google Scholar]
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2023 Ishtiaque Ali Langah, Nayyer IZ Zaman, Habibullah, Zahida Anwar, Ikram Ullah, Muhammad Asad, Jamshed Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
